Spleen tyrosine kinase (SYK) and Bruton’s tyrosine kinase (BTK) inhibitors have emerged as promising targeted therapies for adult immune thrombocytopenia (ITP). Here, SYK is linked to autoimmune thrombocytopenic purpura.